MedPath

A relapse prevention study for anxiety patients who want to discontinue antidepressant medication.

Suspended
Conditions
Remitted anxiety disorder patients: panic disorder with of without agoraphobia, social phobia and generalized anxiety disorder
Registration Number
NL-OMON21398
Lead Sponsor
GGZ InGeest (partner van VUMC)
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Suspended
Sex
Not specified
Target Recruitment
220
Inclusion Criteria

Included are adults aged 18-65 years, who:

1. Use antidepressants for panic disorder (with or without agoraphobia), social phobia or generalized anxiety disorder;

Exclusion Criteria

Patients with comorbid dementia, psychotic disorder, alcohol or drug dependence or who do not speak Dutch are excluded.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome measure is relapse within a year.
Secondary Outcome Measures
NameTimeMethod
1. Time to relapse;<br /><br>2. One-year course of anxiety symptoms;<br /> <br>3. Quality of life;<br /><br>4. Patient satisfaction;<br /><br>5. Predictors of relapse;<br /><br>6. Cost-effectivity;<br /><br>7. Cost-utility.
© Copyright 2025. All Rights Reserved by MedPath